Tool identifies COVID-19 patients at highest risk of deterioration

Frontline doctors and nurses treating a coronavirus patient in ICU

A new risk-stratification tool has been developed by researchers from the UK Coronavirus Clinical Characterisation Consortium (known as ISARIC4C).

The tool can accurately predict the likelihood of deterioration in adults hospitalised with COVID-19.

ISARIC4C was funded as part of a joint rapid research response by:

  • UK Research and Innovation
  • Department of Health and Social Care through the National Institute for Health Research (NIHR).

Available to NHS doctors

Researchers say the online tool, made freely available to NHS doctors, could support clinicians’ decision making – helping to improve patient outcomes and ultimately save lives.

The tool assesses 11 measurements routinely collected from patients including age, gender, and physical measurements (such as oxygen levels) along with some standard laboratory tests. It calculates a percentage risk of deterioration, known as the ‘4C Deterioration Score’.

This innovation, published in The Lancet Respiratory Medicine, builds on the consortium’s previous work developing the ‘4C mortality score’ to predict the percentage risk of death from COVID after admission to hospital.

The ‘4C mortality score’ is already recommended for use by NHS England to guide anti-viral treatments (Remdesivir). Doctors will now see both the ‘4C deterioration score’ and the ‘4C mortality score’ at the same time, using the same tool.

Planning ahead

Co-senior and corresponding author, Professor Mahdad Noursadeghi, UCL Infection & Immunity, said:

Accurate risk-stratification at the point of admission to hospital will give doctors greater confidence about clinical decisions and planning ahead for the needs of individual patients.

The addition of the new 4C deterioration score alongside the 4C mortality score will provide clinicians with an evidence-based measure to identify those who will need increased hospital support during their admission, even if they have a low risk of death.

The tool was developed using data from 74,944 individuals with COVID-19 admitted to 260 hospitals across England, Scotland and Wales, between 6 February and 26 August 2020.

Using a multivariable logistic regression model (where several measures are used to predict an outcome), researchers tested the 11 measures (age/gender/physical measures/lab tests) against the large patient cohort. This established how, and to what to degree each of the measures affected the likelihood of deterioration.

Tool performance

Furthermore, researchers assessed how well the tool performed in nine NHS regions and found that it performed similarly well in each, suggesting that it is likely to be useful across the NHS. Importantly, the new risk score showed superior performance across the NHS, in comparison to previous risk scores.

First author Dr Rishi Gupta, UCL Institute of Global Health, said:

The scale and wide geographical coverage of the ISARIC4C study across the country was critical to the development of this prediction tool. Our analysis provides very encouraging evidence that the 4C Deterioration tool is likely to be useful for clinicians across England, Scotland and Wales to support clinical decision-making.

Automatically generated risk scores

The tool can potentially be incorporated into NHS Trusts’ Electronic Health Record System – used to manage all patient care – so that risk scores are automatically generated for patients.

Researchers suggest that the tool could also be used in other countries for risk-stratification, but should first be evaluated to test its accuracy in these settings.

ISARIC4C is a UK-wide consortium of NHS doctors and scientists from universities including:

  • UCL
  • Imperial College London
  • University of Liverpool
  • The University of Edinburgh
  • University of Oxford.

Top image: Credit: Morsa Images/GettyImages

NOTEThis is the first phase of our new website – let us know if you have feedback or would like to help us test new developments.